{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-082850","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-07-13T11:11:25+00:00","discovered_at":"2026-07-13T11:15:00.468268+00:00","generated_at":"2026-07-13T11:15:30.661646+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Armata receives FDA agreement on pediatric study plan for AP-SA02 in S. aureus bacteremia","bullets":["FDA agreed on Initial Pediatric Study Plan (iPSP) for AP-SA02 as adjunct treatment for complicated S. aureus bacteremia in patients up to 17 years.","iPSP agreement is a regulatory requirement that must be met before submitting a Biologics License Application (BLA).","Pediatric studies will be deferred until adult Phase 3 safety/efficacy data are available; adult Phase 3 expected to start H2 2026.","CEO Dr. Deborah Birx highlighted the milestone as addressing vulnerable pediatric populations with limited treatment options.","AP-SA02 has QIDP and Fast Track designations; Phase 2a results presented at IDWeek 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-082850","json":"https://secwatch.observer/filing/0001104659-26-082850.json","markdown":"https://secwatch.observer/filing/0001104659-26-082850.md","text":"https://secwatch.observer/filing/0001104659-26-082850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/0001104659-26-082850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/tm2620286d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T11:15:30.661646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}